^

    About Us

    VERI is a data platform to link predictive biomarkers in oncology and drug response.


    The database was created by a global team of expert analysts at LARVOL VERI, a technology company with 15 years of experience in data curation for the pharmaceutical and biotechnology industry.


    The goal of VERI is to become the most broad and relied upon tool for physicians, researchers and industry leaders who are involved in precision medicine.


    By using this database, you are agreeing to our

    Terms of Services
    and
    Privacy Policy.


    VERI covers broad array of genetic alterations, types of markers, expression changes, complex phenotypes.

    Genes

    4211

    Biomarkers

    6346

    Cancers

    160

    Drugs

    5710

    Drug classes

    913

    Tests

    834

    Companies

    359

    VERI aims to cover the full development cycle capturing data ranging from preclinical to guidelines to regulatory approvals.

    A1 Approval

    1888

    A2 Guideline

    3629

    B Late Trial

    3359

    C Early Trial

    29202

    D Preclinical

    5827